168 related articles for article (PubMed ID: 22551655)
21. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
Zhou Y; Othus M; Araki D; Wood BL; Radich JP; Halpern AB; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
Leukemia; 2016 Jul; 30(7):1456-64. PubMed ID: 27012865
[TBL] [Abstract][Full Text] [Related]
22. Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation.
Di Grazia C; Pozzi S; Geroldi S; Grasso R; Miglino M; Colombo N; Tedone E; Luchetti S; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Raiola AM; Dominietto A; Varaldo R; Galaverna F; Ghiso A; Sica S; Bacigalupo A
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1242-1246. PubMed ID: 26970379
[TBL] [Abstract][Full Text] [Related]
23. Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation.
Pan X; Gao M; Sun Y; Zhou Y; Wang K; Wang Y; Xu L; Zhang X; Huang X; Zhao XS
Int J Lab Hematol; 2022 Jun; 44(3):510-517. PubMed ID: 35061336
[TBL] [Abstract][Full Text] [Related]
24. How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?
Xu J; Jorgensen JL; Wang SA
Clin Lab Med; 2017 Dec; 37(4):787-802. PubMed ID: 29128069
[TBL] [Abstract][Full Text] [Related]
25. Chimerism evaluation in measurable residual disease-suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
Semchenkova A; Brilliantova V; Shelikhova L; Zhogov V; Illarionova O; Mikhailova E; Raykina E; Skorobogatova E; Novichkova G; Maschan A; Maschan M; Popov A
Cytometry B Clin Cytom; 2021 Sep; 100(5):568-573. PubMed ID: 33369016
[TBL] [Abstract][Full Text] [Related]
26. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
Shapiro RM; Kim DDH
Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.
Ouyang J; Goswami M; Peng J; Zuo Z; Daver N; Borthakur G; Tang G; Medeiros LJ; Jorgensen JL; Ravandi F; Wang SA
Am J Clin Pathol; 2016 Jun; 145(6):769-77. PubMed ID: 27298396
[TBL] [Abstract][Full Text] [Related]
28. Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation.
Waterhouse M; Pfeifer D; Duque-Afonso J; Follo M; Duyster J; Depner M; Bertz H; Finke J
Clin Chem Lab Med; 2019 Apr; 57(5):641-647. PubMed ID: 30457973
[TBL] [Abstract][Full Text] [Related]
29. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
Paiva B; Vidriales MB; Sempere A; Tarín F; Colado E; Benavente C; Cedena MT; Sánchez J; Caballero-Velazquez T; Cordón L; Garces JJ; Simoes C; Martínez-Cuadrón D; Bernal T; Botella C; Grille S; Serrano J; Rodríguez-Medina C; Algarra L; Alonso-Domínguez JM; Amigo ML; Barrios M; García-Boyero R; Colorado M; Pérez-Oteyza J; Pérez-Encinas M; Costilla-Barriga L; Sayas MJ; Pérez O; González-Díaz M; Pérez-Simón JA; Martínez-López J; Sossa C; Orfao A; San Miguel JF; Sanz MÁ; Montesinos P;
Leukemia; 2021 Aug; 35(8):2358-2370. PubMed ID: 33526859
[TBL] [Abstract][Full Text] [Related]
30. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities.
Chen X; Wood BL
Blood Rev; 2017 Mar; 31(2):63-75. PubMed ID: 27742133
[TBL] [Abstract][Full Text] [Related]
31. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
[TBL] [Abstract][Full Text] [Related]
32. Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients.
Sun Y; Zhu G; Zhong H
Eur J Haematol; 2024 Jun; 112(6):870-878. PubMed ID: 38342613
[TBL] [Abstract][Full Text] [Related]
33. Combined usage of Wilms' tumor gene quantitative analysis and multiparameter flow cytometry for minimal residual disease monitoring of acute myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation.
Hao Y; Cheng Y; Wu Q; Zhang A; Jiang X; Xu X
Exp Ther Med; 2018 Feb; 15(2):1403-1409. PubMed ID: 29434724
[TBL] [Abstract][Full Text] [Related]
34. Assessment of WT1 Expression as a Marker of Treatment Outcome in Karyotype Normal Acute Myeloid Leukemia Patients in Pakistan.
Ahmed ZA; Shaikh MS; Moatter T
J Coll Physicians Surg Pak; 2016 May; 26(5):441-2. PubMed ID: 27225156
[TBL] [Abstract][Full Text] [Related]
35. Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML.
Klyuchnikov E; Christopeit M; Badbaran A; Bacher U; Fritzsche-Friedland U; von Pein UM; Wolschke C; Kröger N
Eur J Haematol; 2021 May; 106(5):606-615. PubMed ID: 33249666
[TBL] [Abstract][Full Text] [Related]
36. Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts.
Chea M; Rigolot L; Canali A; Vergez F
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396825
[TBL] [Abstract][Full Text] [Related]
37. [Monitoring of minimal residual disease after HLA-mismatched allogeneic hematopoietic stem cell transplantation using six-color based HLA-Flow method in pediatric acute leukemia].
Sakamoto K; Tomoyasu C; Yano M; Tamura S; Osone S; Imamura T; Umeda K; Hiramatsu H; Ishida H; Inaba T; Kuroda H; Adachi S; Hosoi H
Rinsho Ketsueki; 2017; 58(7):729-737. PubMed ID: 28781266
[TBL] [Abstract][Full Text] [Related]
38. [Clinical Significance of Minimal Residual Disease Monitoring by Multi-parameter Flow Cytometry before Allogeneic Hematopoietic Stem Cell Transplantation for Prognosis of Acute Leukemia Patients].
Liu C; Liu L; Chen JB; Tang XQ; Xiao Q; Zhang HB; Wang JY; Wang L; Zhan Q; Wang X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):262-266. PubMed ID: 32027287
[TBL] [Abstract][Full Text] [Related]
39. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
Fuda F; Chen W
Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression.
Jacobsohn DA; Loken MR; Fei M; Adams A; Brodersen LE; Logan BR; Ahn KW; Shaw BE; Kletzel M; Olszewski M; Khan S; Meshinchi S; Keating A; Harris A; Teira P; Duerst RE; Margossian SP; Martin PL; Petrovic A; Dvorak CC; Nemecek ER; Boyer MW; Chen AR; Davis JH; Shenoy S; Savasan S; Hudspeth MP; Adams RH; Lewis VA; Kheradpour A; Kasow KA; Gillio AP; Haight AE; Bhatia M; Bambach BJ; Haines HL; Quigg TC; Greiner RJ; Talano JM; Delgado DC; Cheerva A; Gowda M; Ahuja S; Ozkaynak M; Mitchell D; Schultz KR; Fry TJ; Loeb DM; Pulsipher MA
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2040-2046. PubMed ID: 29933069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
